Drug Acceleration Experts Launch New Biotech Startup With Eye on Cancer Treatments, Global Partnerships for Patients
DURHAM, N.C., March 17, 2022 /PRNewswire/ -- The team of entrepreneur physician-scientists who first developed the novel therapeutic RABI-767 for the treatment of severe acute pancreatitis have launched a new biotech startup to accelerate the development of novel therapeutics for major unmet needs and difficult-to-treat diseases. The startup, Lamassu Bio, Inc., will first focus its research efforts on the development of novel therapeutics for the treatment of multiple cancers, including pancreatic cancer.
- The startup, Lamassu Bio, Inc., will first focus its research efforts on the development of novel therapeutics for the treatment of multiple cancers, including pancreatic cancer.
- These new partnerships will allow scientists to utilize global research knowledge and expertise to accelerate the development and commercialization of therapeutics.
- "We believe our methods, which have already proven successful in the United States, can benefit patients worldwide.
- Rabi Hanna, MD and Greg Palmer, PhD, founded Lamassu Pharma, LLC, a biotech startup, in partnership with the Mayo Clinic.